Patent SG-11201808822U-A (SG)
Title: Cancer biomarkers and methods of use
Inventor: LIM BING
IPC: C12Q1/68
Filed: 2017-04-06
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010111110111010111111101011101111101111101111011111 International Bureau 0.. .1 j ..... ..or::,„, (10) International Publication Number (43) International Publication Date WO 2017/176215 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/7088 (2006.01) C12Q 1/68 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, C12N 15/113 (2010.01) A61P 35/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/SG2017/050197 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 6 April 2017 (06.04.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 10201602700P 6 April 2016 (06.04.2016) SG GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Connexis North Tower, Singapore 138632 (SG). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: LIM, Bing; c/o Genome Institute of Singapore, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, 60 Biopolis Street, #02-01, Singapore 138672 (SG). GW, KM, ML, MR, NE, SN, TD, TG). ZHANG, Wencai; c/o Genome Institute of Singapore, 60 Declarations under Rule 4.17: Biopolis Street, #02-01, Singapore 138672 (SG). TAM, of inventorship (Rule 4.17(N)) Biopol- Wai Leong; c/o Genome Institute of Singapore, 60 Published: is Street, #02-01, Singapore 138672 (SG). LTD; — with international search report (Art. 21(3)) (74) Agent: SPRUSON & FERGUSON (ASIA) PTE Singapore _ with sequence listing part of description (Rule 5.2(a)) for every AL, AM, P.O. Box 1531, Robinson Road Post Office, 903031 (SG). (81) Designated States (unless otherwise indicated, kind of national protection available): AE, AG, OF USE (54) Title: CANCER BIOMARKERS AND METHODS Fig. 16 C.ell swim 4 Profiling..., Lims -\"\". anti-trARNA ;$ MOTSv Se 0 Turnorigenic A i. traF24246 N s 0/ Moto 11 trot-1.290 .4 N.., ‘ Theropy-tesponso ir) iNon-invosive biornarffer) Il arcuttiorw cevree TdRotaa in blood ei IN (57) : The present disclosure relates to a method of determining the presence of lung cancer in a subject comprising the IN ----. steps of detecting an expression level of miR-1246 alone or in combination with an expression level of miR-1290 in a sample ob - IN tamedfrom the subject wherein the increase in miR-1246 and/or miR-1290 in the sample obtained from the subject relative to the C expression level of miR-1246 or miR-1290 in the control sample indicates the presence of lung cancer in the subject. The disclosure N further comprises a method of monitoring a response to therapy in a lung cancer patient, a method of prognosis of lung cancer in a O patient and a method for treating lung cancer in a subject comprising the use of inhibitors of miR-1246 and/or miR-1290 alone or in combination. In a specific embodiment, miR-1246 and/or miR-1290 levels are used to predict response to chemotherapy and pro - .,. gression in human non-small cell lung cancer (NSCLC) patients.